In recent decades, diabetes has become one of the global diseases threatening human health. Among them, type 1 diabetes accounted for about 10%, mainly insulin deficiency, mostly in childhood or adolescence. In the treatment of type 1 diabetes, insulin secreting beta cells are very important. Islet transplantation is the most effective beta cell replacement therapy to achieve accurate blood glucose control. < / P > < p > it is worth noting that some patients with type 1 diabetes mellitus may transplant islet cells into the liver, but this treatment can lead to complications such as bleeding, thrombosis and graft rejection. < p > < p > at 23:00 p.m. on September 7, Beijing time, the sub Journal of nature, a top academic journal, was published In a new study published online, researchers from the University of Pennsylvania and other teams said they have developed a new method of subcutaneous transplantation of islet cells to keep blood glucose levels stable in animal models of type 1 diabetes. The results of this study may be of great significance in improving the treatment of this autoimmune disease. The corresponding author of the paper is Ali Naji, a professor of surgery at the University of Pennsylvania School of medicine, an internationally renowned transplant surgeon and immunologist. It is mentioned in the paper that the location of subcutaneous transplantation has attracted attention because it is easy to reach and monitor, and the subcutaneous represents another safe and convenient islet transplantation site. However, the new problem is that the lack of neovascularization and the resulting death of hypoxic cells greatly limit the life span and function of the grafts, which also hinders the wide clinical application of islet transplantation. < / P > < p > in this study, the team overcame this problem by wrapping islet cells in a new collagen matrix that helps cells survive after subcutaneous transplantation. < / P > < p > the team also used rodents, pigs and human islets to verify that their transplantation method can provide continuous normal blood glucose, and demonstrated its effectiveness in non-human primate islet transplantation models. < / P > < p > the team also believes that their method can also be used to improve the viability of other types of transplanted cells. For example, if stem cell-derived beta cells can also be treated in this way, they may become a renewable source of insulin secreting cells to replace those lost in patients with type 1 diabetes. < / P > < p > the team concluded that this is a simple, safe and repeatable method that allows animals to maintain normal insulin and glucagon production. “Although further research is needed, islet subcutaneous transplantation may provide a new treatment option for patients with type 1 diabetes.” Global Tech